Thoratec Stock Gain Driven By Debut Of HeartMate II For Heart Failure
This article was originally published in The Gray Sheet
Executive Summary
Thoratec's recent launch of its HeartMate II continuous-flow ventricular assist device for advanced heart failure is driving sales growth that helped push the firm's stock up 51% in the third quarter to $26.25